Stratec SE
XETRA:SBS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (22.8), the stock would be worth €37.46 (104% upside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 11.2 | €18.4 |
0%
|
| 3-Year Average | 22.8 | €37.46 |
+104%
|
| 5-Year Average | 25.9 | €42.53 |
+131%
|
| Industry Average | 16.2 | €26.59 |
+45%
|
| Country Average | 15.5 | €25.53 |
+39%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
€342.1m
|
/ |
Oct 2025
€28.3m
|
= |
|
|
€342.1m
|
/ |
Dec 2025
€24.3m
|
= |
|
|
€342.1m
|
/ |
Dec 2026
€30.7m
|
= |
|
|
€342.1m
|
/ |
Dec 2027
€35.6m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| DE |
|
Stratec SE
XETRA:SBS
|
223.7m EUR | 11.2 | 14.3 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 55.9 | 60 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 18.8 | 25.2 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 23.9 | 38.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 18.8 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 25.3 | 31.8 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40B EUR | 15.1 | 18.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 27.2 | 45.5 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 33.3 | 42.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 16.6 | 24.7 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 16.8 | 21.6 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 10.6 |
| Median | 15.5 |
| 70th Percentile | 23.1 |
| Max | 672.9 |
Other Multiples
Stratec SE
Glance View
STRATEC SE engages in the design and manufacture of automated analyzer systems in the fields of clinical diagnostic and biotechnology. The company is headquartered in Birkenfeld, Baden-Wuerttemberg and currently employs 1,398 full-time employees. Its business activities are divided into three segments: Instrumentation, which designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers; Diatron, which offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications, and Consumables, which develops and sells scientific materials, such as nucleic acid purification and designs and produces smart consumables in the fields of diagnostics, life sciences, and medical technology. In addition, the Company develops workflow software for networking various analyzer systems, as well as develops and sells scientific materials and technologies.
